BRAF V600EBiomarker (exploratory)ESMO 2025來源:人工整理

EC+mFOLFOX6 vs EC vs SOC

關鍵結果C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%

化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制

詳細證據整理

Circulating Tumor (ct)DNA Analysis of BRAF V600E Dynamics and Changes in Genomic Landscape in Patients with First-Line BRAF V600E-Mutant mCRC Treated in BREAKWATER

Authors: Kopetz S, Shah K, Yoshino T, Yaeger R, Eng C, Van Cutsem E, et al.
Presented at: ESMO 2025 (Oral Presentation)
Study: BREAKWATER (Phase 3)
Note: This is a conference presentation. No peer-reviewed journal full text is available.

Key Findings

ctDNA vs Tissue Concordance

Concordance between ctDNA-based and tissue-based BRAF V600E detection was 87.4%.

Baseline BRAF V600E VAF and Outcomes

EC+mFOLFOX6 demonstrated ORR and OS benefit independent of baseline BRAF V600E variant allele frequency (VAF), indicating that the treatment effect was consistent regardless of baseline ctDNA levels.

ctDNA Dynamics at Cycle 2, Day 15 (C2D15)

Detected-to-Not Detected (D/ND) conversion rates at C2D15 by treatment arm:

Arm D/ND Conversion Rate
EC+mFOLFOX6 67.1%
EC alone 45.2%
Control (SOC) 37.5%

Prognostic Value of ctDNA Clearance

Patients who achieved D/ND conversion (ctDNA clearance) had substantially improved outcomes:

  • Median OS = Not Estimable (NE) for D/ND patients
  • HR 0.30 vs patients who remained D/D (detected/detected)

Resistance Mutations at Cycle 7, Day 1 (C7D1)

Emergence of resistance mutations differed significantly by treatment arm:

Arm Resistance Mutations at C7D1
EC+mFOLFOX6 6.6%
EC alone 37.9%

These findings suggest that the addition of chemotherapy to EC significantly delays the emergence of resistance mutations, potentially explaining the superior duration of response and survival seen with the triplet combination.

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • GuidelineJNCCN 2026來源:摘要

    NCCN Colon Cancer v3.2026(Guidelines Insights)

    BRAF V600E 晚期治療推薦更新, 晚期治療章節依 biomarker 重組; 新增 fluoropyrimidine 前 DPYD 檢測; 依近期試驗更新非轉移性輔助治療

    NCCN 結腸癌 v3.2026 依 biomarker 重組晚期治療章節,並特別更新 BRAF V600E 推薦,承接 BREAKWATER 證據;另新增化療前 DPYD 檢測建議。Insights 摘要未列推薦等級,細節需對照指引全文

  • Phase 3 (Cohort 3)ASCO GI 2026來源:人工整理

    EC+FOLFIRI vs FOLFIRI±bev (1L)

    ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%

    FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌

  • Phase 3 RCTNat Med 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    ORR 60.9% vs 40.0%, OR 2.44

    BREAKWATER 首報:一線 EC+化療 ORR 達 61%,FDA 加速核准

  • Phase 3 RCT (updated)NEJM 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    mPFS 12.8 vs 7.1 mo; mOS 30.3 vs 15.1 mo, HR 0.49

    mOS 30.3 個月——BRAF V600E mCRC 首次追上 BRAF wt 的存活。死亡風險減半

看 BRAF V600E 的全部文獻